Pletal (Cilostazol) - Summary

PLETAL SUMMARY

PLETAL (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III).

PLETAL is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

See all Pletal indications & dosage >>

PLETAL NEWS HIGHLIGHTS

Published Studies Related to Pletal (Cilostazol)

Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. [2008.08]

Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury. [2008.06]

Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). [2008.02]

Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. [2008]

Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. [2007.08.15]

more >>

Clinical Trials Related to Pletal (Cilostazol)

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg [Completed]

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon [Completed]

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon [Completed]

Post-Marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) [Active, not recruiting]

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness [Recruiting]

more >>